UA99337C2 - Жидкая лекарственная форма фсг - Google Patents

Жидкая лекарственная форма фсг

Info

Publication number
UA99337C2
UA99337C2 UAA201010809A UAA201010809A UA99337C2 UA 99337 C2 UA99337 C2 UA 99337C2 UA A201010809 A UAA201010809 A UA A201010809A UA A201010809 A UAA201010809 A UA A201010809A UA 99337 C2 UA99337 C2 UA 99337C2
Authority
UA
Ukraine
Prior art keywords
fsh
liquid formulation
preservatives
pharmaceutical composition
benzyl alcohol
Prior art date
Application number
UAA201010809A
Other languages
English (en)
Ukrainian (uk)
Inventor
Саша Штольценбергер
Эрих Колер
Original Assignee
Биодженерикс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биодженерикс Аг filed Critical Биодженерикс Аг
Publication of UA99337C2 publication Critical patent/UA99337C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Изобретение касается фармацевтической композиции, которая содержит фолликулостимулирующий гормон (ФСГ) или его вариант, а также хлорид бензалкония и бензиловый спирт в качестве консервантов.
UAA201010809A 2008-02-08 2009-02-09 Жидкая лекарственная форма фсг UA99337C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08151231 2008-02-08

Publications (1)

Publication Number Publication Date
UA99337C2 true UA99337C2 (ru) 2012-08-10

Family

ID=40568186

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201010809A UA99337C2 (ru) 2008-02-08 2009-02-09 Жидкая лекарственная форма фсг

Country Status (27)

Country Link
US (4) US20110054410A1 (ru)
EP (2) EP2412385A1 (ru)
JP (1) JP5620824B2 (ru)
KR (2) KR101573773B1 (ru)
CN (3) CN104688679A (ru)
AT (1) ATE523209T1 (ru)
AU (1) AU2009211331B2 (ru)
BR (1) BRPI0908887B8 (ru)
CA (2) CA2926500A1 (ru)
CY (1) CY1112082T1 (ru)
DE (1) DE202009009905U1 (ru)
DK (1) DK2249869T3 (ru)
EA (1) EA019530B1 (ru)
ES (1) ES2372470T3 (ru)
HK (1) HK1149494A1 (ru)
HR (1) HRP20110801T1 (ru)
IL (1) IL206759A (ru)
ME (1) ME01337B (ru)
MX (1) MX2010008802A (ru)
NZ (1) NZ586588A (ru)
PL (1) PL2249869T3 (ru)
PT (1) PT2249869E (ru)
RS (1) RS52106B (ru)
SI (1) SI2249869T1 (ru)
UA (1) UA99337C2 (ru)
WO (1) WO2009098318A1 (ru)
ZA (1) ZA201004457B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
BR122013025625B1 (pt) 2008-10-17 2021-08-03 Sanofi-Aventis Deutschland Gmbh Composição farmacêutica, seu uso e método de preparação da mesma, kit e dispositivo
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
MY159565A (en) 2009-11-13 2017-01-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
JP5800527B2 (ja) * 2010-03-30 2015-10-28 日東電工株式会社 安定化医薬組成物、安定化医薬組成物溶液製剤、フィルム状製剤及びフィルム状製剤の製造方法
AR081755A1 (es) * 2010-04-02 2012-10-17 Hanmi Holdings Co Ltd Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo
HUE031181T2 (en) 2010-08-30 2017-06-28 Sanofi Aventis Deutschland Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
KR101983982B1 (ko) 2011-08-29 2019-05-30 사노피-아벤티스 도이칠란트 게엠베하 2형 당뇨병 환자의 혈당 조절에 사용하기 위한 약제학적 병용물
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
CN103917107A (zh) * 2011-11-09 2014-07-09 安迪苏法国联合股份有限公司 包含蛋氨酸的屠宰前饮食
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN105727260A (zh) * 2016-02-03 2016-07-06 华侨大学 一种卵泡刺激素的长效制剂
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
CN105726468A (zh) * 2016-02-28 2016-07-06 中国农业科学院特产研究所 梅花鹿用超数排卵聚乙烯吡咯烷酮fsh复合缓释注射剂
US10085971B2 (en) * 2016-08-22 2018-10-02 Navinta Iii Inc Pharmaceutical solution of asenapine for sublingual or buccal use
CN108728465A (zh) * 2017-04-14 2018-11-02 深圳新诺微环生物科技有限公司 一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用
US20230364172A1 (en) * 2022-05-14 2023-11-16 Syncotrance, LLC Modulation of solubility, palatability, absorption, and bioavailability of mitragyna speciosa-derived compounds for oral and buccal delivery

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840896A (en) 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
US4923805A (en) 1983-11-02 1990-05-08 Integrated Genetics, Inc. Fsh
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
CA2018676C (en) 1989-06-20 2003-05-06 Christie A. Kelton Novel heteropolymeric protein production methods
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4440587A1 (de) 1994-11-14 1996-05-15 Fliether Karl Gmbh & Co Basquill-Schloß
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
WO1998058957A2 (en) 1997-06-25 1998-12-30 Applied Research Systems Ars Holding N.V. Disulfide cross-linked glycoprotein hormone analogs, their preparation and use
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
PL346127A1 (en) * 1998-07-23 2002-01-28 Lilly Co Eli Fsh and fsh variant formulations, products and methods
AU779005B2 (en) 1999-04-16 2004-12-23 Instituto Massone S.A. Highly purified gonadotropin compositions and process for preparing them
AU2001231531A1 (en) 2000-02-11 2001-08-20 Maxygen Aps Follicle stimulating hormones
DE10249817A1 (de) 2002-10-24 2004-05-13 Daimlerchrysler Ag Schaltanordnung zur Betätigung von Beleuchtungssystemen an einem Kraftfahrzeug
MXPA05010635A (es) 2003-04-02 2005-12-12 Ares Trading Sa Formulaciones farmaceuticas liquidas de hormona estimulante de foliculos y hormona luteinizante junto con un surfactante no ionico.
EA008924B1 (ru) 2003-12-22 2007-08-31 Арес Трейдинг С.А. Способ очистки фсг
ES2312037T3 (es) 2004-11-09 2009-02-16 Ares Trading S.A. Metodo para puruficar fsh.
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
NZ581702A (en) 2007-06-28 2011-10-28 Biogenerix Ag Follicle stimulating hormone producing cell clone

Also Published As

Publication number Publication date
AU2009211331B2 (en) 2014-07-03
NZ586588A (en) 2012-10-26
US20160303201A1 (en) 2016-10-20
EA201070940A1 (ru) 2010-12-30
ME01337B (me) 2013-12-20
KR20150138428A (ko) 2015-12-09
CN110433136A (zh) 2019-11-12
KR101573773B1 (ko) 2015-12-02
BRPI0908887A2 (pt) 2015-09-15
PL2249869T3 (pl) 2012-02-29
BRPI0908887B8 (pt) 2021-05-25
CA2713386A1 (en) 2009-08-13
CY1112082T1 (el) 2015-11-04
IL206759A0 (en) 2010-12-30
AU2009211331A1 (en) 2009-08-13
HRP20110801T1 (hr) 2011-12-31
WO2009098318A1 (en) 2009-08-13
IL206759A (en) 2015-02-26
BRPI0908887B1 (pt) 2021-01-19
DK2249869T3 (da) 2011-12-12
JP2011514317A (ja) 2011-05-06
MX2010008802A (es) 2011-03-29
RS52106B (en) 2012-08-31
ES2372470T3 (es) 2012-01-20
DE202009009905U1 (de) 2009-10-29
KR101662631B1 (ko) 2016-10-05
CN104688679A (zh) 2015-06-10
JP5620824B2 (ja) 2014-11-05
EA019530B1 (ru) 2014-04-30
SI2249869T1 (sl) 2012-01-31
EP2412385A1 (en) 2012-02-01
KR20100123697A (ko) 2010-11-24
ATE523209T1 (de) 2011-09-15
ZA201004457B (en) 2011-05-25
CA2713386C (en) 2016-04-19
HK1149494A1 (en) 2011-10-07
PT2249869E (pt) 2011-12-16
US20110054410A1 (en) 2011-03-03
EP2249869B1 (en) 2011-09-07
US20160303238A1 (en) 2016-10-20
EP2249869A1 (en) 2010-11-17
CN101970010A (zh) 2011-02-09
US20160303202A1 (en) 2016-10-20
CA2926500A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
UA99337C2 (ru) Жидкая лекарственная форма фсг
WO2012160180A3 (en) Pharmaceutical composition for administration to nails
MY167691A (en) A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
UA107814C2 (ru) Спирооксиндольные антагонисты mdm 2
WO2011104381A3 (en) Stable antibody containing compositions
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
MX2015000813A (es) Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
MY153976A (en) Lh liquid formulations
WO2011141685A3 (fr) Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants
PH12017501003B1 (en) Aminoacid-based composition for fibroelastin recovery in dermal connective tissues
MX2015016825A (es) Compuestos de pirazol como moduladores del receptor de hormona estimuladora de foliculos y sus usos.
MX348531B (es) Dispositivo de lata de aerosol para suministro tópico dual.
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
WO2011126940A3 (en) Topical uses of szeto-schiller peptides
WO2012092350A3 (en) Topical uses szeto-schiller peptides
AU2009298305A8 (en) Pharmaceutical composition utilising combinations of variants of the gonadotropin-liberating hormone (GnRH) as immunogen
WO2014039074A3 (en) Therapeutic compositions and related methods
MX370990B (es) Ésteres de ácidos oligo-hidroxicarboxílicos y uso de los mismos.
WO2011113785A3 (en) A cosmetic composition for rejuvenating skin appearance
CL2008001615A1 (es) Compuestos derivados de di(hetero)aril-ciclohexano; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cardiopatias, arritmias, isquemias, entre otras.
PL2026879T3 (pl) Zastosowanie peptydów jako wyszczuplających substancji czynnych
WO2014039412A8 (en) Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
WO2012047007A3 (ko) 손톱 또는 발톱 성장 촉진용 조성물
IT1394921B1 (it) Uso di composti come principi attivi per migliorare l'azione di riparazione cellulare dell'epidermide umana, e composizioni farmaceutiche e cosmetiche che li contengono
IN2014CH00799A (ru)